Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City. The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented by Wa'el Hashad, Chief Executive Officer.
Hashad will be speaking on the panel 'Emerging Frontiers in Neuroscience' and will also be available for investor one-on-one meetings. Longeveron has made its investor presentation for the conference accessible in the 'Events & Presentations' section of the company's website, allowing interested parties to review the materials in advance.
Longeveron Inc. (NASDAQ: LGVN), un'azienda biotecnologica in fase clinica specializzata in medicina rigenerativa, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale ROTH sulle Opportunità Sanitarie che si terrà il 9 ottobre 2024 a New York City. L'azienda, che si concentra sullo sviluppo di terapie cellulari per condizioni legate all'invecchiamento, sia croniche che potenzialmente letali, sarà rappresentata da Wa'el Hashad, Amministratore Delegato.
Hashad parteciperà al panel 'Frontiere Emergenti nella Neuroscienza' e sarà disponibile anche per incontri individuali con gli investitori. Longeveron ha reso accessibile la sua presentazione per gli investitori nella sezione 'Eventi & Presentazioni' del sito web dell'azienda, permettendo così alle parti interessate di rivedere i materiali in anticipo.
Longeveron Inc. (NASDAQ: LGVN), una compañía de biotecnología en etapa clínica especializada en medicina regenerativa, ha anunciado su participación en la 3ª Conferencia Anual ROTH sobre Oportunidades en Salud que se llevará a cabo el 9 de octubre de 2024 en la ciudad de Nueva York. La compañía, que se enfoca en el desarrollo de terapias celulares para condiciones relacionadas con el envejecimiento, tanto crónicas como potencialmente mortales, estará representada por Wa'el Hashad, Director Ejecutivo.
Hashad participará en el panel 'Fronteras Emergentes en Neurociencia' y también estará disponible para reuniones individuales con inversores. Longeveron ha hecho accesible su presentación para inversores en la sección 'Eventos y Presentaciones' del sitio web de la compañía, permitiendo así que las partes interesadas revisen los materiales con anticipación.
롱제버론 Inc. (NASDAQ: LGVN), 임상 단계 재생 의학 생명공학 회사는 제3회 연례 ROTH 의료 기회 컨퍼런스에 2024년 10월 9일 뉴욕시에서 참여한다고 발표했습니다. 생명을 위협하는 만성 노화 관련 질환을 위한 세포 치료 개발에 중점을 두고 있는 이 회사는 와엘 하샤드, 최고 경영자가 대표합니다.
하샤드는 '신경과학의 새로운 영역' 패널에서 연설하며, 또한 투자자와의 일대일 미팅을 위해 이용 가능합니다. 롱제버론은 컨퍼런스를 위한 투자자 프레젠테이션을 회사 웹사이트의 '이벤트 및 프레젠테이션' 섹션에 공개하여, 관심 있는 당사자들이 미리 자료를 검토할 수 있도록 하고 있습니다.
Longeveron Inc. (NASDAQ: LGVN), une société de biotechnologie en phase clinique spécialisée dans la médecine régénérative, a annoncé sa participation à la 3ème Conférence Annuelle ROTH sur les Opportunités de Santé qui se tiendra le 9 octobre 2024 à New York. La société, qui se concentre sur le développement de thérapies cellulaires pour les conditions d'âge liées à la vie, à la fois graves et chroniques, sera représentée par Wa'el Hashad, Directeur Général.
Hashad participera au panel 'Nouveaux Horizons en Neuroscience' et sera également disponible pour des réunions individuelles avec des investisseurs. Longeveron a rendu accessible sa présentation pour les investisseurs dans la section 'Événements & Présentations' de son site web, permettant ainsi aux parties intéressées de consulter les documents à l'avance.
Longeveron Inc. (NASDAQ: LGVN), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf regenerative Medizin spezialisiert hat, hat seine Teilnahme an der 3. jährlichen ROTH Healthcare Opportunities Conference am 9. Oktober 2024 in New York City angekündigt. Das Unternehmen, das sich auf die Entwicklung von Zelltherapien für lebensbedrohliche und chronische altersbedingte Erkrankungen konzentriert, wird vertreten durch Wa'el Hashad, Chief Executive Officer.
Hashad wird im Panel 'Emerging Frontiers in Neuroscience' sprechen und steht auch für persönliche Gespräche mit Investoren zur Verfügung. Longeveron hat seine Investorenpräsentation für die Konferenz in der 'Veranstaltungen & Präsentationen'-Sektion der Unternehmenswebsite zugänglich gemacht, sodass interessierte Parteien die Materialien im Voraus einsehen können.
- None.
- None.
MIAMI, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York City, including Wa’el Hashad, Chief Executive Officer, speaking on the panel “Emerging Frontiers in Neuroscience” and investor 1x1 meetings.
The Longeveron investor presentation to be used at the conference is available at the “Events & Presentations” section of the Company’s website.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When and where is Longeveron (LGVN) participating in the ROTH Healthcare Opportunities Conference?
What panel will Longeveron's CEO be speaking on at the ROTH conference?
Where can investors find Longeveron's (LGVN) presentation for the ROTH conference?
What type of company is Longeveron (LGVN)?
